Partner Therapeutics Begins Phase 2 Trial of Inhaled Leukine for COVID-19

Partner Therapeutics has enrolled the first patient in a phase 2 trial evaluating its inhaled Leukine (sargramostim) for hospitalized COVID-19 patients.

The U.S. trial will assess whether the drug can improve clinical outcomes in patients with acute hypoxemia. It will enroll 60 patients who will either receive standard of care alone or Leukine in addition to standard care.

The trial is one of two studies of inhaled Leukine as a potential treatment for COVID-19 supported by a $35 million contract from the  Department of Defense.